These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28858862)

  • 1. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
    Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
    Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and application of patient-derived xenograft models in pancreatic cancer research.
    Wang CF; Shi XJ
    Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
    Allaway RJ; Fischer DA; de Abreu FB; Gardner TB; Gordon SR; Barth RJ; Colacchio TA; Wood M; Kacsoh BZ; Bouley SJ; Cui J; Hamilton J; Choi JA; Lange JT; Peterson JD; Padmanabhan V; Tomlinson CR; Tsongalis GJ; Suriawinata AA; Greene CS; Sanchez Y; Smith KD
    Oncotarget; 2016 Mar; 7(13):17087-102. PubMed ID: 26934555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
    Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
    Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Medicine and Pancreatic Cancer.
    George B
    Surg Oncol Clin N Am; 2021 Oct; 30(4):693-708. PubMed ID: 34511190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized RNA Medicine for Pancreatic Cancer.
    Gilles ME; Hao L; Huang L; Rupaimoole R; Lopez-Casas PP; Pulver E; Jeong JC; Muthuswamy SK; Hidalgo M; Bhatia SN; Slack FJ
    Clin Cancer Res; 2018 Apr; 24(7):1734-1747. PubMed ID: 29330203
    [No Abstract]   [Full Text] [Related]  

  • 10. Precision medicine in pancreatic cancer: treating every patient as an exception.
    Herbst B; Zheng L
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):805-810. PubMed ID: 31511204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
    Iovanna J; Dusetti N
    Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
    Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
    Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
    Witkiewicz AK; Balaji U; Eslinger C; McMillan E; Conway W; Posner B; Mills GB; O'Reilly EM; Knudsen ES
    Cell Rep; 2016 Aug; 16(7):2017-31. PubMed ID: 27498862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.
    Gerber MH; Underwood PW; Judge SM; Delitto D; Delitto AE; Nosacka RL; DiVita BB; Thomas RM; Permuth JB; Hughes SJ; Wallet SM; Judge AR; Trevino JG
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine.
    Di Franco G; Usai A; Funel N; Palmeri M; Montesanti IER; Bianchini M; Gianardi D; Furbetta N; Guadagni S; Vasile E; Falcone A; Pollina LE; Raffa V; Morelli L
    World J Gastroenterol; 2020 Jun; 26(21):2792-2809. PubMed ID: 32550755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
    Aguirre AJ; Nowak JA; Camarda ND; Moffitt RA; Ghazani AA; Hazar-Rethinam M; Raghavan S; Kim J; Brais LK; Ragon D; Welch MW; Reilly E; McCabe D; Marini L; Anderka K; Helvie K; Oliver N; Babic A; Da Silva A; Nadres B; Van Seventer EE; Shahzade HA; St Pierre JP; Burke KP; Clancy T; Cleary JM; Doyle LA; Jajoo K; McCleary NJ; Meyerhardt JA; Murphy JE; Ng K; Patel AK; Perez K; Rosenthal MH; Rubinson DA; Ryou M; Shapiro GI; Sicinska E; Silverman SG; Nagy RJ; Lanman RB; Knoerzer D; Welsch DJ; Yurgelun MB; Fuchs CS; Garraway LA; Getz G; Hornick JL; Johnson BE; Kulke MH; Mayer RJ; Miller JW; Shyn PB; Tuveson DA; Wagle N; Yeh JJ; Hahn WC; Corcoran RB; Carter SL; Wolpin BM
    Cancer Discov; 2018 Sep; 8(9):1096-1111. PubMed ID: 29903880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma.
    Gao W; Zhou Y; Li Q; Zhou Q; Tan L; Song Y; Zhao X; Yu M; Zheng S; Ye H; Zeng B; Lin Q; Zhou J; Liu Y; Huang H; Zhang H; Hu X; Li Z; Dai X; Chen R
    Diabetologia; 2015 Apr; 58(4):835-44. PubMed ID: 25636208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Ponz-Sarvise M; Tuveson DA; Yu KH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.